GYKI-52466
GYKI-52466 is a non-competitive antagonist at the AMPA receptor, a type of ionotropic glutamate receptor. It was first synthesized and studied by the Hungarian pharmaceutical company Gedeon Richter in the 1980s. GYKI-52466 is known for its selectivity and potency, and it has been widely used in scientific research to understand the function and pharmacology of AMPA receptors.
Chemistry[edit | edit source]
GYKI-52466 is a derivative of quinazolinone, a nitrogenous heterocyclic compound. It is a 2,3-benzodiazepine compound, which is a class of drugs that includes many well-known anxiolytic and hypnotic medications. However, unlike these drugs, GYKI-52466 does not act on the GABA receptor, but instead selectively blocks the AMPA receptor.
Pharmacology[edit | edit source]
The primary mechanism of action of GYKI-52466 is as a non-competitive antagonist at the AMPA receptor. This means that it does not compete with the natural ligand, glutamate, for the binding site, but instead binds to a separate site on the receptor and inhibits its function. This inhibition prevents the flow of ions through the receptor, thereby reducing neuronal excitability.
Research and Clinical Implications[edit | edit source]
Research on GYKI-52466 has contributed significantly to our understanding of the AMPA receptor and its role in various neurological and psychiatric disorders. For example, it has been used in studies investigating the role of AMPA receptors in epilepsy, schizophrenia, depression, and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
While GYKI-52466 itself has not been developed for clinical use due to its poor oral bioavailability and short half-life, its discovery has led to the development of other AMPA receptor antagonists that are currently in clinical use or undergoing clinical trials. These include perampanel, which is approved for the treatment of epilepsy, and decaboxyl-biotin-ligand conjugated AMPA receptor antagonists, which are being investigated for their potential in treating neurodegenerative diseases.
See Also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
